11 Most Undervalued Blue Chip Stocks to Buy Now

3. Sanofi (NASDAQ:SNY)

Forward Price-to-Earnings Multiple: 9.78

Upside Potential: 21.60%

Number of Hedge Fund Holders: 32

Sanofi (NASDAQ:SNY) is one of the most undervalued blue chip stocks to buy now.

On January 6, 2026, Barclays downgraded Sanofi (NASDAQ:SNY) from ‘Overweight’ to ‘Equal Weight’, while setting an EUR 85 price target. The firm’s update reflects its more cautious long-term outlook on the company despite the strong operational outlook and an undemanding valuation. Barclays recommends caution due to concerns around limited late-stage pipeline depth and the approaching loss of exclusivity for Dupixent. The bank sees the loss as a growing overhang on the company’s medium- to long-term growth profile despite solid near-term execution expectations.

Meanwhile, Sanofi (NASDAQ:SNY) reported a regulatory win on January 5, 2025, when the FDA accepted the supplemental BLA for Tzield for priority review to further its use in children as young as one year old with stage 2 type 1 diabetes. The filing, supported by interim Phase 4 PETITE-T1D data, reflects the company’s ability to extend lifecycle value from its existing assets. The FDA decision is expected to come out by April 29, 2026.

At the same time, on December 30, 2025, TD Cowen cited pipeline risk, while reiterating a ‘Hold’ rating following a  Complete Response Letter for tolebrutinib. The firm expects long-term sales to decline sharply despite diversification from the Dynavax acquisition.

Sanofi (NASDAQ:SNY), a global biopharmaceutical company, focuses on specialty care, vaccines, and general medicines. It combines research and development with global commercial scale across diversified therapeutic franchises.